Filing summary
Important identity and period discrepancy: The supplied filing is for Trail One, Inc., not Citius Pharmaceuticals, Inc. It is a Form 10-Q for the quarter ended June 30, 2011 (the third quarter of Trail One’s fiscal year, which ends September 30). Investors should verify the company and filing before relying on this summary.
Business context and reporting period
Trail One describes itself as a development-stage company formed in September 2010 to market customized automobile license-plate tags as accessories. It reported no sales and had not commenced major operations. The statements cover the three and nine months ended June 30, 2011 and, in some schedules, the period from inception. The filing does not provide a prior-year comparable quarter.
Financial results and liquidity
- Revenue: $0 for the three and nine months ended June 30, 2011.
- Expenses and loss: Three-month operating expenses were $7,095 and net loss was $7,315, including $220 of interest expense. Nine-month operating expenses were $23,196 and net loss was $23,583, including $387 of interest expense.
- Cash flow: Cash used in operating activities was $15,840 for the nine months. Financing provided $13,405 from related-party borrowing; cash declined by $2,435 to $65.
- Balance sheet at June 30, 2011: Cash and total assets were $65; current liabilities were $21,148, including a $13,405 demand loan from the founder/CEO and $387 accrued related-party interest. Working capital and stockholders’ equity were each negative $21,083. Accumulated deficit was $39,083.
- Debt and ownership: The unsecured founder/CEO loan bears 8% interest and is due on demand. The company reported 18,000,000 common shares outstanding as of August 26, 2011.
Changes, outlook, and risks
Compared with September 30, 2010, cash fell from $2,500 to $65, liabilities rose from zero to $21,148, and equity declined from $2,500 to a deficit of $21,083. These are balance-sheet comparisons, not year-over-year operating comparisons.
Management said the company needed additional financing to fund operations and its business plan, and disclosed substantial doubt about its ability to continue as a going concern. It estimated a monthly burn rate of approximately $2,620, said it expected insufficient revenue to cover expenses for at least the next 12 months, and discussed raising capital through equity, debt, or private financing. It also cited a $75,000 funding need to complete its marketing program and planned an online sales site for September 2011. Financing availability and terms were uncertain; failure to obtain funds could force the company to cease operations. Potential equity financing could dilute current holders, while debt could impose senior claims and operating restrictions.
The filing describes an intended retail price of about $150 for its product, but notes that no definitive orders had been placed and manufacturing, packaging, shipping, and marketing cost assumptions could be wrong. Disclosure controls were reported ineffective, citing no independent board or audit committee, limited segregation of duties, and reliance on a financial consultant for financial reporting. The company said it planned to address these weaknesses when resources allowed. It reported no material legal proceedings, no unregistered equity sales, and no defaults on senior securities.
Internal inconsistency: The business description concerns automobile tags, but the section on satisfying cash obligations refers to revenue from “liquid gels.” The filing text does not clarify this reference.
Key facts for investors to verify
- Confirm that this Trail One filing—not a Citius Pharmaceuticals filing—is the intended document and that June 30, 2011 is the intended reporting period.
- Verify the company’s cash runway, the status and terms of planned financing, and whether the demand loan was repaid or extended.
- Check whether the planned website, product launch, and stated $150 retail pricing were achieved, and validate product cost assumptions and customer demand.
- Clarify the “liquid gels” reference and assess whether the ineffective disclosure controls were subsequently remediated.